CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation

Liang,Min; Zhao,Tiangang; Ma,Linfeng; Guo,Yingjie

doi:10.3892/or.2017.6168

CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation

Authors:
- Min Liang
- Tiangang Zhao
- Linfeng Ma
- Yingjie Guo
View Affiliations

Affiliations: School of Life Sciences, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: December 20, 2017 https://doi.org/10.3892/or.2017.6168
Pages: 1322-1330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibition of checkpoint kinase 1 (CHK1) is a promising therapeutic strategy to increase the effectiveness of DNA-damaging drugs in pancreatic cancer. However, owing to the multiple roles of CHK1 in the DNA damage response (DDR) pathway, the molecular mechanism of chemosensitization by CHK1 inhibitors is not definitive. In the present study, we explored the antitumor mechanism of LY2603618, a specific CHK1 inhibitor, alone or in combination with gemcitabine in 5 pancreatic cancer cell lines. LY2603618 treatment of the pancreatic cancer cell lines resulted in growth inhibition, with IC50 values ranging from 0.89 to 2.75 µM, but limited cell death. Importantly, treatment of pancreatic cancer cell lines with LY2603618 reduced the levels of pCDC25C, pCDK1, and pCDK2, accompanied by DNA damage and RRM1/2 downregulation. Furthermore, LY2603618 synergized with gemcitabine treatment to induce growth inhibition and apoptosis in pancreatic cancer cells. Mechanistic investigations showed that gemcitabine sensitization by CHK1 inhibition was associated with CDK‑dependent RRM1/2 downregulation and DNA damage enhancement. These findings provide a basis for further development of combining CHK1 inhibitors and gemcitabine to treat pancreatic cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
3	Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:6110–6117. 1991.PubMed/NCBI
4	Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gäbele E, Hinke A, Hollerbach C and Endlicher E: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: A multicentre phase II study. Br J Cancer. 100:1032–1036. 2009. View Article : Google Scholar : PubMed/NCBI
5	Li J and Saif MW: Advancements in the management of pancreatic cancer. JOP. 10:109–117. 2009.PubMed/NCBI
6	Dai Y and Grant S: New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 16:376–383. 2010. View Article : Google Scholar : PubMed/NCBI
7	Löffler H, Rebacz B, Ho AD, Lukas J, Bartek J and Kramer A: Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle. 5:2543–2547. 2006. View Article : Google Scholar : PubMed/NCBI
8	Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C and Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol. 142:1534–1543. 1993.PubMed/NCBI
9	Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, et al: Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70:4972–4981. 2010. View Article : Google Scholar : PubMed/NCBI
10	Buisson R, Boisvert JL, Benes CH and Zou L: Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress durings phase. Mol Cell. 59:1011–1024. 2015. View Article : Google Scholar : PubMed/NCBI
11	Nordlund P and Reichard P: Ribonucleotide reductases. Annu Rev Biochem. 75:681–706. 2006. View Article : Google Scholar : PubMed/NCBI
12	King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, Cox K, Guo S and Marshall M: Characterization and preclinical development of LY2603618: A selective and potent Chk1 inhibitor. Invest New Drugs. 32:213–226. 2014. View Article : Google Scholar : PubMed/NCBI
13	Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, Diaz HB, Barnard D, Merzoug FF, Huber L, et al: Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs. 32:955–968. 2014. View Article : Google Scholar : PubMed/NCBI
14	Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein HJ and Ravindranath Y: Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 94:1393–1400. 1999.PubMed/NCBI
15	Xie C, Edwards H, Xu X, Zhou H, Buck SA, Stout ML, Yu Q, Rubnitz JE, Matherly LH, Taub JW and Ge Y: Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res. 16:5499–5510. 2010. View Article : Google Scholar : PubMed/NCBI
16	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, et al: Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One. 7:e520952012. View Article : Google Scholar : PubMed/NCBI
18	Edwards H, Xie C, La Fiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH and Ge Y: RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood. 114:2744–2752. 2009. View Article : Google Scholar : PubMed/NCBI
19	Xie C, Drenberg C, Edwards H, Caldwell JT, Chen W, Inaba H, Xu X, Buck SA, Taub JW, Baker SD and Ge Y: Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One. 8:e791062013. View Article : Google Scholar : PubMed/NCBI
20	Wang FZ, Fei HR, Cui YJ, Sun YK, Li ZM, Wang XY, Yang XY, Zhang JG and Sun BL: The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Apoptosis. 19:1389–1398. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kasahara K, Goto H, Enomoto M, Tomono Y, Kiyono T and Inagaki M: 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J. 29:2802–2812. 2010. View Article : Google Scholar : PubMed/NCBI
22	Clarke CA and Clarke PR: DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system. Biochem J. 388:705–712. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F and Abraham RT: Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell. 19:607–618. 2005. View Article : Google Scholar : PubMed/NCBI
24	Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS and Maybaum J: Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther. 8:45–54. 2009. View Article : Google Scholar : PubMed/NCBI
25	Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, et al: Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle. 6:104–110. 2007. View Article : Google Scholar : PubMed/NCBI
26	Barnard D, Diaz HB, Burke T, Donoho G, Beckmann R, Jones B, Barda D, King C and Marshall M: LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Invest New Drugs. 34:49–60. 2016. View Article : Google Scholar : PubMed/NCBI
27	Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM and Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
28	Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, Van den Ijssel P, Ylstra B and Peters GJ: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 65:9510–9516. 2005. View Article : Google Scholar : PubMed/NCBI